Parkinson’s disease is fundamentally a brain disease. It progressively destroys specific populations of nerve cells, starting deep in the brainstem and spreading upward over years or even decades. By the time the characteristic tremor or stiffness appears, at least 75% of the dopamine-producing neurons in a critical brain region have already been lost.
Where the Damage Starts
Parkinson’s doesn’t begin where most people expect. The earliest damage occurs in the lower brainstem, specifically in a structure called the dorsal motor nucleus of the vagus nerve, which controls basic functions like digestion and heart rate. It also appears early in the olfactory bulb, the brain’s smell-processing center. This is why many people develop a reduced sense of smell and constipation years before any movement problems show up.
From these starting points, the disease climbs upward through the brain in a roughly predictable sequence. It next reaches areas in the brainstem that regulate sleep, mood, and alertness. Only after that does it hit the substantia nigra, a small, darkly pigmented region in the midbrain that produces dopamine. This is the stage where the classic motor symptoms, tremor, slowness, and rigidity, finally become noticeable. Later still, the damage can spread into the cortex, the brain’s outer layer responsible for thinking, memory, and perception.
This staged progression, first described by the neuropathologist Heiko Braak, explains something that puzzles many patients: the non-motor symptoms they experienced for years were not separate problems. They were the disease itself, already at work in the brain long before a diagnosis was possible.
What Kills the Neurons
At the molecular level, the damage traces back to a protein called alpha-synuclein. In a healthy brain, this protein plays a normal role in nerve cell communication. In Parkinson’s, it misfolds and clumps together into dense, tangled fibers. These clumps, known as Lewy bodies, accumulate inside neurons and eventually kill them.
The toxic protein clusters don’t just sit passively inside cells. They trigger a cascade of internal damage: they disrupt the cell’s energy-producing machinery (mitochondria), overwhelm its waste-disposal systems, and generate oxidative stress, essentially corroding the cell from within. As neurons die and release these misfolded proteins, neighboring cells can take them up and begin the same destructive process, which helps explain why the disease spreads progressively through connected brain regions.
The Brain’s Immune System Turns Harmful
The brain has its own immune cells, called microglia, that normally protect neurons by clearing debris and fighting infection. In Parkinson’s, these cells become chronically overactivated. Instead of protecting neurons, they release a sustained flood of inflammatory molecules that damage the very cells they’re meant to defend.
This chronic inflammation accelerates the disease in several ways. The inflammatory signals can promote further misfolding of alpha-synuclein, damage mitochondria in nearby neurons, and even break down the blood-brain barrier, allowing immune cells from the rest of the body to enter brain tissue where they don’t belong. Activated microglia also send signals that convert another type of brain support cell, astrocytes, into a reactive form that is directly toxic to neurons. In animal studies, removing microglia from the equation significantly reduces the nerve cell death caused by alpha-synuclein, confirming that this inflammatory cycle is not just a bystander effect but a key driver of the disease.
How Dopamine Loss Disrupts Movement
The movement problems in Parkinson’s come down to a circuit imbalance in a group of deep brain structures called the basal ganglia. Under normal conditions, dopamine from the substantia nigra fine-tunes two opposing pathways in this circuit: a “go” pathway that promotes movement and a “stop” pathway that inhibits it. When dopamine drops, the balance tips sharply toward the stop pathway. The result is the hallmark combination of slowness (bradykinesia), muscle rigidity, and tremor.
This isn’t just a theoretical model. When researchers artificially activated the stop pathway in healthy mice, the animals developed Parkinson’s-like symptoms. When they stimulated the go pathway in mice with dopamine depletion, the motor symptoms improved. The circuit works like a seesaw, and losing dopamine pushes it decisively in one direction. This is also why dopamine-replacing medications can be so effective early in the disease: they partially restore the balance. But as more neurons die, the remaining cells can no longer compensate, and the medication becomes less reliable.
Cognitive and Emotional Effects
Parkinson’s affects far more than movement. Dopamine loss in the prefrontal cortex, the brain’s planning and decision-making center, leads to a range of cognitive difficulties. These include problems with working memory (holding information in mind while using it), slower processing speed, trouble with planning and attention, and reduced impulse control. These symptoms can appear even in patients who show no signs of dementia and may fluctuate alongside motor symptoms.
Meanwhile, the early destruction of brainstem regions that produce norepinephrine, a chemical messenger involved in alertness and mood regulation, drives many of the emotional and sleep-related symptoms. Depression and anxiety are among the most common non-motor symptoms of Parkinson’s, and they’re not simply a reaction to having a chronic illness. They result from physical damage to the brain circuits that regulate emotion. Sleep disturbances, including vivid dreaming, disordered breathing during sleep, and excessive daytime drowsiness, affect nearly all Parkinson’s patients to some degree and are linked to the same brainstem damage.
Effects on the Autonomic Nervous System
The brain also controls functions you never think about: blood pressure regulation, digestion, bladder control, and sexual function. Parkinson’s damages the brainstem nuclei and hypothalamic regions that manage these automatic processes. This is why many patients experience orthostatic hypotension (a sudden drop in blood pressure when standing up), chronic constipation, urinary urgency, and swallowing difficulties. These autonomic symptoms can be among the most disruptive aspects of the disease, sometimes more so than the motor problems, and they tend to worsen as the disease progresses.
The Scale of the Problem
Parkinson’s is the fastest-growing neurological condition in the world. A 2025 modeling study published in the BMJ projected that 25.2 million people will be living with the disease globally by 2050, a 112% increase from 2021. Even after adjusting for aging populations, the prevalence rate is expected to rise 55%, suggesting that factors beyond demographics are contributing to the increase. The disease typically begins its silent work in the brain a decade or more before diagnosis, meaning many of those future patients already have early-stage changes underway in their brainstems today.